BioCentury
ARTICLE | Distillery Therapeutics

Cancer

January 17, 2018 7:29 PM UTC

Patient sample and cell culture studies suggest IFNB1 could help treat breast cancer. In breast tissue samples from patients with invasive ductal carcinoma, levels of IFNB1 were higher in tumors than in normal breast tissue, and in triple-negative breast cancer (TNBC) patients, low tumor levels of an IFNB1-induced gene signature were associated with poor overall survival. In human mammary epithelial cell-derived cancer stem cells, IFNB1 decreased the epithelial-to-mesenchymal transition (EMT), growth, tumorsphere formation and migration compared with no treatment. Next steps could include testing IFNB1 in additional models of breast cancer.

Novartis AG markets Betaferon interferon β-1b, an interferon β-1b-based immune modulator, to treat multiple sclerosis. ...

BCIQ Company Profiles

Case Western Reserve University

BCIQ Target Profiles

Interferon (IFN) beta (IFNB1)